Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

159.61 -1.03 (-0.64%)
Streaming Delayed Price Updated: 1:30 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
3 Things About Johnson & Johnson That Smart Investors Know
J&J shares have missed out on the market rally so far this year. 
Via The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
Recent bumps in the road won't deter these companies. 
Via The Motley Fool
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
Better Buy: J&J vs. Kenvue
You can count on both of these companies for passive income, too. 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
Via Benzinga
Could This Issue Sink Johnson & Johnson's Stock Price?
Don't be too quick to press the sell button. 
Via The Motley Fool
2 Incredibly Cheap Dividend Stocks to Buy Now
High-quality dividend stocks are rarely cheap. These two names are an exception. 
Via The Motley Fool
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
Market crashes are inevitable, but certain stocks could limit potential damage. 
Via The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long way when it's invested in industry-leading businesses. 
Via The Motley Fool
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape. 
Via InvestorPlace
3 High-Quality Dividend Stocks Yielding 3%-Plus to Buy for Decades of Rising Income
These companies generate durable and growing cash flows. 
Via The Motley Fool
3 Great Dividend Stocks You Can Buy for Less Than $50
These steady-Eddie operators are perfect bedrock stocks for investors despite trading for less than $50. 
Via The Motley Fool
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders  
Via Benzinga
The 3 Most Undervalued Dow Stocks to Buy in September 2023
These undervalued Dow stocks have multiple, strong and positive catalysts and are poised to deliver strong returns for investors. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Lawsuit Against Dummy Pills For Allergy, Cold: Johnson & Johnson And Procter & Gamble Face Allegations
In a recent lawsuit, Johnson & Johnson (NYSE: JNJ) and Procter & Gamble Co (NYSE: PG) are facing allegations of misleading consumers regarding decongestant cold medicines conta 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Watch in the ‘Green Zone’
Now may be the time to take a look at these three blue-chips, as each one is currently in the "Green Zone stocks" category. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Warren Buffett Stocks That Are Near Their 52-Week Lows
Should you consider loading up on these stocks? 
Via The Motley Fool
Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains
Unearth the three best healthcare stocks to buy that are poised for long-term growth ahead for savvy investors. 
Via InvestorPlace
Here's My Top Growth Stock to Buy in 2023
The growth train is leaving the station and you don't want to miss it. Find out why this stock remains a strong buy even after doubling in 2023. 
Via The Motley Fool
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
Exposures Product Safety
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
3 Bulletproof Stocks to Buy Before the Next Recession Strikes
With these three bulletproof stocks, investors seek refuge in stable and growth-oriented stocks as the specter of economic downturns looms. 
Via InvestorPlace
Topics Economy
Exposures Economy
Warren Buffett's Highest-Yielding Stock Isn't Citigroup at 5%. He's Netting Almost 57% Annually From Another Top Holding.
Relative to Berkshire's cost basis in the company, this longtime Buffett holding is generating more than 11 times the nominal yield of Citigroup. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.